Molecular pathogenesis in non-Hodgkin lymphoma

Implications for therapy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Although Diffuse Large B-Cell lymphoma (DLBCL) represents 30% of all non-Hodgkin lymphomas, there are many different subtypes of DLBCL with various prognostic implications. We are now recognizing that the molecular subtype of the DLBCL may be associated with specific clinical characteristics as well as outcome of the treatment. With this additional information, we may be able to better select a treatment for the patient which will improve the expected response. Only large scale clinical testing will help us with understanding these molecular subtypes and designing therapies for patients with DLBCL.

Original languageEnglish (US)
Pages (from-to)155-156
Number of pages2
JournalTransfusion and Apheresis Science
Volume49
Issue number2
DOIs
StatePublished - Oct 1 2013

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Molecular pathogenesis in non-Hodgkin lymphoma : Implications for therapy. / Vose, Julie Marie.

In: Transfusion and Apheresis Science, Vol. 49, No. 2, 01.10.2013, p. 155-156.

Research output: Contribution to journalReview article

@article{4ae6fc43215a4aac81c221f63494dad2,
title = "Molecular pathogenesis in non-Hodgkin lymphoma: Implications for therapy",
abstract = "Although Diffuse Large B-Cell lymphoma (DLBCL) represents 30{\%} of all non-Hodgkin lymphomas, there are many different subtypes of DLBCL with various prognostic implications. We are now recognizing that the molecular subtype of the DLBCL may be associated with specific clinical characteristics as well as outcome of the treatment. With this additional information, we may be able to better select a treatment for the patient which will improve the expected response. Only large scale clinical testing will help us with understanding these molecular subtypes and designing therapies for patients with DLBCL.",
author = "Vose, {Julie Marie}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.transci.2013.07.019",
language = "English (US)",
volume = "49",
pages = "155--156",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Molecular pathogenesis in non-Hodgkin lymphoma

T2 - Implications for therapy

AU - Vose, Julie Marie

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Although Diffuse Large B-Cell lymphoma (DLBCL) represents 30% of all non-Hodgkin lymphomas, there are many different subtypes of DLBCL with various prognostic implications. We are now recognizing that the molecular subtype of the DLBCL may be associated with specific clinical characteristics as well as outcome of the treatment. With this additional information, we may be able to better select a treatment for the patient which will improve the expected response. Only large scale clinical testing will help us with understanding these molecular subtypes and designing therapies for patients with DLBCL.

AB - Although Diffuse Large B-Cell lymphoma (DLBCL) represents 30% of all non-Hodgkin lymphomas, there are many different subtypes of DLBCL with various prognostic implications. We are now recognizing that the molecular subtype of the DLBCL may be associated with specific clinical characteristics as well as outcome of the treatment. With this additional information, we may be able to better select a treatment for the patient which will improve the expected response. Only large scale clinical testing will help us with understanding these molecular subtypes and designing therapies for patients with DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=84886639987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886639987&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2013.07.019

DO - 10.1016/j.transci.2013.07.019

M3 - Review article

VL - 49

SP - 155

EP - 156

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -